Rezolute (RZLT) Research & Development (2010 - 2026)
Rezolute (RZLT) posted Research & Development of $11.4 million for Q1 2026, down 20.46% sequentially from $14.3 million in Q4 2025, and down 25.33% YoY from $15.3 million in Q1 2025.
Rezolute (RZLT) Research & Development (2010 - 2026) Analysis & Trends
Rezolute has reported Research & Development for 16 years, with the latest figure at $11.4 million in Q1 2026.
- Quarterly Research & Development fell 25.33% year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.8 million (changed 0.03% YoY) and the FY2025 annual result came in at $61.5 million, up 10.38% from the prior year.
- Research & Development declined to $11.4 million in Q1 2026 per RZLT's latest filing, from $14.3 million in the prior quarter.
- Over five years, Research & Development peaked at $20.9 million in Q2 2025 and troughed at $7.7 million in Q3 2022.
- A 5-year average of $12.8 million and a median of $12.4 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2026: Research & Development soared 131.13% in 2022, then dropped 25.33% in 2026.
- Over 5 years, Research & Development stood at $10.9 million in 2022, then advanced by 10.0% to $12.0 million in 2023, then gained by 4.88% to $12.6 million in 2024, then gained by 13.63% to $14.3 million in 2025, then fell by 20.46% to $11.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $11.4 million, $14.3 million, and $13.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - | 11.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.41 Mn |
| Dec 31, 2025 | 14.35 Mn |
| Sep 30, 2025 | 13.15 Mn |
| Jun 30, 2025 | 20.86 Mn |
| Mar 31, 2025 | 15.28 Mn |
| Dec 31, 2024 | 12.63 Mn |
| Sep 30, 2024 | 12.75 Mn |
| Jun 30, 2024 | 19.09 Mn |
| Mar 31, 2024 | 12.40 Mn |
| Dec 31, 2023 | 12.04 Mn |
| Sep 30, 2023 | 12.21 Mn |
| Jun 30, 2023 | 10.93 Mn |
| Mar 31, 2023 | 14.23 Mn |
| Dec 31, 2022 | 10.95 Mn |
| Sep 30, 2022 | 7.70 Mn |
| Jun 30, 2022 | 8.57 Mn |
| Mar 31, 2022 | 8.69 Mn |
| Dec 31, 2021 | 9.45 Mn |
| Sep 30, 2021 | 5.77 Mn |
| Jun 30, 2021 | 4.39 Mn |